Free beta — full access, free until October 2026. No card, no auto-charge — paid plans are opt-in when they launch.
Company
IMMUNIC, INC. (IMUX)
Standardized SEC financial data for IMMUNIC, INC. — income statement, balance sheet, cash flow and 40+ ratios, available as a clean JSON API. CIK 0001280776 · NASDAQ · Pharmaceutical Preparations.
Return on equity
1000.0%
Free cash flow
-$86.0M
Current ratio
0.75×
EPS (diluted)
$-0.62
Income statement
USD
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
R&D expense
$38.6M
$61.1M
$71.3M
$83.2M
$80.0M
$82.0M
SG&A expense
$10.3M
$13.3M
$15.3M
$16.0M
$18.0M
$21.2M
Operating income
-$49.0M
-$91.7M
-$119.5M
-$99.2M
-$98.1M
-$103.2M
EBITDA
-$48.9M
-$91.6M
Standardized from IMMUNIC, INC.'s SEC filings — per-share figures split-adjusted. Full history via the API.